Drug Therapy and Interactions in Pediatric Oncology A Pocket Guide
Carolina Witchmichen Penteado Schmidt
Drug Therapy and Interactions in Pediatric Oncology A Pocket Guide - illustrated - Curitiba Paraná Brazil: Springer, c2016 - 212 pages
There are few publications about drug interactions in chemotherapy and even less about pediatric oncology treatment. For this reason, the present book is intended to offer guidelines about drug interactions for physicians, pharmacists and the other healthcare professionals involved in the chemotherapy of pediatric patients. In this book the reader will have access to a primary introduction for the major diseases in pediatric oncology, followed by the major therapeutic protocols. Following that, the most important drug interactions in pediatric oncology treatment are presented and discussed in detail. Finally, important topics such as Drug-Food Interactions are addressed. Drug Therapy and Interactions in Pediatric Oncology focuses in great detail on the drug interactions in Pediatric Oncohematology and will be an indispensable resource in daily practice for a wide range of health providers.
331938872X 9783319388724 = 1–2 years old acid acute lymphoblastic leukemia acute lymphoid leukemia acute myeloid leukemia Administration Dose Days Aprepitant Ara-C Based on information bone marrow Burkitt’s lymphoma cell chemotherapy chemotherapy drug childhood cancer cisplatin clinical Cyclophosphamide Cytarabine Decrease of clearance dexamethasone diagnosed disease Dose of intrathecal doxorubicin Drug Administration Dose Drug interactions involving enzymes Etoposide French Society German Leukemia Treatment Hemorio 29 high-risk patients Hodgkin lymphoma hydrocortisone IC-BFM 2002 protocol idarubicin Ifosfamide imatinib incidence rate information from Hemorio inhibition inhibitor intrathecal intrathecal cytarabine irinotecan leucovorin Leukemia Treatment Group lymphoblastic leukemia treatment lymphoid leukemia patients malignant Mercaptopurine metabolism methotrexate mL NaCl 0.9 neoplasms non-Hodgkin lymphoma Oral 60 P-glycoprotein Pediatric Oncology LMB86 phase for acute Prednisone Prednisone Oral protein protocol for Burkitt’s protocol for high-risk receptor Society of Pediatric Source standard-risk Substrate 60 system B non-Hodgkin T-cell Table toxicity Treatment Group BFM2004 Treatment Group BFM95 tumors vinblastine vincristine voriconazole
-- Medicine-- Tumors in children -- Chemotherapy-- Pediatric pharmacology--Medical / Gynecology & Obstetrics--Pediatric pharmacology-- Tumors in children -- Chemotherapy--Medical -- Oncology--Medical -- Hematology--Medical -- Pharmacology-- Medical -- Pharmacy--Oncology--Haematology--Pharmacology--Pharmacy / dispensing-- Pediatrics--Oncology --Hematology--Oncology-- Pharmacy--Medical -- Pediatrics--Paediatric medicine-- Medical / Pharmacy--Medical / Pharmacology-- Medical / Pediatrics --Medical / Oncology / General--Medical / Hematology --Medical / Clinical Medicine -- Medical › Oncology › General
618.92994 WIT
Drug Therapy and Interactions in Pediatric Oncology A Pocket Guide - illustrated - Curitiba Paraná Brazil: Springer, c2016 - 212 pages
There are few publications about drug interactions in chemotherapy and even less about pediatric oncology treatment. For this reason, the present book is intended to offer guidelines about drug interactions for physicians, pharmacists and the other healthcare professionals involved in the chemotherapy of pediatric patients. In this book the reader will have access to a primary introduction for the major diseases in pediatric oncology, followed by the major therapeutic protocols. Following that, the most important drug interactions in pediatric oncology treatment are presented and discussed in detail. Finally, important topics such as Drug-Food Interactions are addressed. Drug Therapy and Interactions in Pediatric Oncology focuses in great detail on the drug interactions in Pediatric Oncohematology and will be an indispensable resource in daily practice for a wide range of health providers.
331938872X 9783319388724 = 1–2 years old acid acute lymphoblastic leukemia acute lymphoid leukemia acute myeloid leukemia Administration Dose Days Aprepitant Ara-C Based on information bone marrow Burkitt’s lymphoma cell chemotherapy chemotherapy drug childhood cancer cisplatin clinical Cyclophosphamide Cytarabine Decrease of clearance dexamethasone diagnosed disease Dose of intrathecal doxorubicin Drug Administration Dose Drug interactions involving enzymes Etoposide French Society German Leukemia Treatment Hemorio 29 high-risk patients Hodgkin lymphoma hydrocortisone IC-BFM 2002 protocol idarubicin Ifosfamide imatinib incidence rate information from Hemorio inhibition inhibitor intrathecal intrathecal cytarabine irinotecan leucovorin Leukemia Treatment Group lymphoblastic leukemia treatment lymphoid leukemia patients malignant Mercaptopurine metabolism methotrexate mL NaCl 0.9 neoplasms non-Hodgkin lymphoma Oral 60 P-glycoprotein Pediatric Oncology LMB86 phase for acute Prednisone Prednisone Oral protein protocol for Burkitt’s protocol for high-risk receptor Society of Pediatric Source standard-risk Substrate 60 system B non-Hodgkin T-cell Table toxicity Treatment Group BFM2004 Treatment Group BFM95 tumors vinblastine vincristine voriconazole
-- Medicine-- Tumors in children -- Chemotherapy-- Pediatric pharmacology--Medical / Gynecology & Obstetrics--Pediatric pharmacology-- Tumors in children -- Chemotherapy--Medical -- Oncology--Medical -- Hematology--Medical -- Pharmacology-- Medical -- Pharmacy--Oncology--Haematology--Pharmacology--Pharmacy / dispensing-- Pediatrics--Oncology --Hematology--Oncology-- Pharmacy--Medical -- Pediatrics--Paediatric medicine-- Medical / Pharmacy--Medical / Pharmacology-- Medical / Pediatrics --Medical / Oncology / General--Medical / Hematology --Medical / Clinical Medicine -- Medical › Oncology › General
618.92994 WIT